AI Insight
This commentary discusses oral ghrelin receptor agonists as a potential therapeutic approach for heart failure with reduced ejection fraction (HFrEF). The article highlights the ongoing need for improved treatments, particularly for advanced heart failure patients, and positions these agonists as inotropic medications that could enhance myocardial contractile function by addressing the intrinsic defects in heart muscle fibers.
Why it matters
If proven effective, oral ghrelin receptor agonists could offer a new treatment option for patients with advanced heart failure who have limited therapeutic alternatives. This approach may improve systolic function and clinical outcomes in a population with substantial morbidity and mortality.
Understand the Science
Heart failure remains a substantial cause of morbidity and mortality. Despite numerous therapeutic advancements over the past decade, there are populations in whom therapy is insufficient, particularly patients with advanced heart failure. Since the inception of therapy for heart failure with reduced ejection fraction (HFrEF), the use of inotropic medications has been considered, with the objective of enhancing the intrinsic defect in myocardial fibres responsible for the decline in contraction force.
Source: [Comment] Oral ghrelin receptor agonist: a new promise for the improvement of systolic function